Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
At this time, the initial consultation is free
Based on the STEP-1 clinical trial, the average weight loss with semaglutide 2.4 mg weekly is 14.9% of body weight over 68 weeks (about 16 months)
When evaluated with more sensitive and reliable 24-h continuous monitoring and in thorough QT studies, two of the long-acting GLP-1 RAs, liraglutide and albiglutide, were shown to cause a pronounced increase in the 24-h time-averaged mean HR from baseline of up to 610 bpm, while for dulaglutide and exenatide LAR, the increase in 24-h mean HR was 34 bpm [23, 24, 27,28,29,30]
see safety resources before assuming any vial is equivalent to clinic care
Our compounded medications are not affiliated with, nor endorsed by, Novo Nordisk, and are not reviewed by the FDA for safety or efficacy.
They can also cause withdrawal when a patient stops using them
